Biomarker ID | 760 |
PMID | 21963599 |
Year | 2012 |
Biomarker | OPNa (osteopontin -a ) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Alpha-V beta-3 integrin/OPN pathway,TWEAK regulation of gene expression,Osteopontin signaling,Osteoclast signaling,Beta-3 integrin cell surface interactions |
Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | Specimens were obtained from 40 PCa and 30 benign prostate hyperplasia (BPH) patients |
Senstivity | 62.5% |
Specificity | 96.7% |
AUC | 0.74 |
Accuracy | 77.1% |
Level Of Significance | p<0.05 |
Method Used | Quantitative real time PCR (qRT-PCR) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | SPP1 |